Italfarmaco Group and Luye Pharma announced today that they entered into a commercialization agreement for Rivastigmine MD. Under the agreement, Milan, Italy-based Italfarmco receives exclusive rights to commercialize the Rivastigmine multi-day transdermal patch in four European companies, according to a news release. Italfarmaco gains the rights to commercialize in Germany, Italy, Portugal and Greece under […]